FDA Makes Post-Market Safety Evaluation Comprehensive For All NMEs, BLAs
Executive Summary
All new molecular entities and BLAs approved since Sept. 27, 2007, will be subject to the comprehensive post-market safety evaluation process that FDA pilot-tested during the past two years